Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with clinically staged II–III pMMR/MSS rectal adenocarcinoma receive long-course chemoradiation with concurrent capecitabine, followed by two cycles of CapeOX chemotherapy and intravenous tislelizumab. Participants are randomized to daily oral Probio-M9 or matched placebo from treatment start until surgery, and all undergo total mesorectal excision (TME). The trial compares the two combination arms to a control arm receiving chemoradiation alone, monitoring safety, imaging and pathological response, and surgical outcomes. Outcomes will use RECIST/MRI and pathology to measure tumor shrinkage and treatment-related adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* ECOG performance status 0-2
* Biopsy-proven rectal adenocarcinoma
* Distal tumor margin within 10 cm of the anal verge
* No distant metastasis
* Clinical stage II or III based on MRI (T4b excluded)
* Maximum diameter of rectal tumor ≥ 10 mm on baseline CT or MRI (measurable lesion according to RECIST 1.1)
* Willing and able to comply with the study protocol
* Willing to provide blood and tissue specimens for research purposes
* No prior anti-tumor treatment (e.g., radiotherapy, chemotherapy, immunotherapy, biological therapy, or herbal therapy)
* No history of immune system disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, HIV infection, etc.)
* No significant dysfunction of major organs (heart, lung, liver, kidney)
* No jaundice or gastrointestinal obstruction
* No acute or ongoing infection
* Adequate hematologic and biochemical function including:

  * Neutrophils ≥ 1.5 × 10\^9/L
  * Hemoglobin ≥ 80 g/L
  * Platelets ≥ 100 × 10\^9/L
  * Serum creatinine ≤ 1.5 × ULN
  * Total bilirubin ≤ 1.5 × ULN
  * ALT and AST ≤ 2.5 × ULN
* No social or psychiatric disorders that may interfere with study participation
* Women of childbearing potential must have a negative pregnancy test before enrollment and must use effective contraception from study entry until 60 days after the last dose of study drug

Exclusion Criteria:

* History of multiple primary cancers or concomitant malignant tumors other than rectal cancer
* Receipt of any anti-cancer treatment (e.g., surgery, chemotherapy, radiotherapy, or other systemic therapies) within the past 5 years
* History of recent major surgery
* Conditions that may affect the gastrointestinal absorption of capecitabine (e.g., inability to swallow, persistent nausea or vomiting, chronic diarrhea)
* Uncontrolled or severe concomitant diseases of any kind
* Known allergy or hypersensitivity to any components of the study drugs
* Estimated life expectancy ≤ 5 years due to any cause
* Planned or prior organ or bone marrow transplantation
* Use of immunosuppressive therapy or systemic corticosteroids for immunosuppressive purposes within 1 month prior to enrollment
* History of central nervous system disorders that may impair the ability to provide informed consent or affect compliance with oral medication (investigator discretion)
* Other conditions that may interfere with study results or lead to premature discontinuation of study treatment (e.g., alcoholism or drug abuse)
* Pregnant or breastfeeding women, or women planning to become pregnant during the treatment period

Where it's running

• Seventh Medical Center of Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Junfeng Du, PhD
• Email: dujunfeng@301hospital.com.cn
• Phone: +86-15810908850

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant tislelizumab plus nab‑paclitaxel before kidney‑sparing distal ureterectomy for ureteral cancer

  This will try giving people with non‑metastatic ureteral cancer two to three cycles of tislelizumab plus nab‑paclitaxel before a kidney‑sparing distal ureterectomy to see if tumor response improves and the treatment is tolerable.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07125547

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Multi-omics blood and CT monitoring for early detection of lung cancer recurrence after neoadjuvant therapy and surgery

  This project tests whether combining blood-based multi-omics (metabolomics and cfDNA), CT radiomics, and AI can noninvasively detect early recurrence after surgery in NSCLC patients treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07291921

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.